Wed, Jun 10, 2026
Amir Asghary1 
, Marie Saghaeian Jazi2 , Seyed Mostafa Mir3 , Abbas Doulani4 , Hamid Reza Joshaghani5
, Marie Saghaeian Jazi2 , Seyed Mostafa Mir3 , Abbas Doulani4 , Hamid Reza Joshaghani5
1- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran. Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. 0000-0003-0344-3870
2- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Information Science, Faculty of Education and Psychology, Alzahra University, Tehran, Iran
5- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 0000-0003-3392-304X ,joshaghani@goums.ac.ir
2- Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
3- Department of Biochemistry and Biophysics, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
4- Department of Information Science, Faculty of Education and Psychology, Alzahra University, Tehran, Iran
5- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 0000-0003-3392-304X ,
Abstract: (152 Views)
Background and Objectives: Gastric cancer (GC), particularly adenocarcinoma, remains a global health burden with high mortality due to late-stage diagnosis and limited reliable biomarkers for disease monitoring. Lipid metabolism plays a crucial role in tumor biology, and serum lipid-related markers, including apolipoproteins, have been suggested as potential non-invasive indicators of tumor progression. This study aimed to evaluate the association between serum lipid profiles and tumor stage and histological grade in patients with gastric adenocarcinoma.
Methods: Fifty patients diagnosed with gastric adenocarcinoma were enrolled. Serum levels of total cholesterol, triglycerides, HDL-C, LDL-C, ApoA1, and ApoB were measured. Patients were categorized into early (stages I–II) and advanced (stages III–IV) tumor stages, as well as into moderately differentiated versus poorly differentiated grades. The Shapiro-Wilk test was used to assess data normality. Parametric and non-parametric tests were applied accordingly. A p-value < 0.05 was considered statistically significant.
Results: ApoB was the only parameter showing a significant association with tumor stage. Patients with advanced-stage GC had significantly lower mean ApoB levels compared to those in early stages (52.4 ± 2.6 vs. 63.4 ± 5.2 mg/dl, p = 0.042). No statistically significant differences were observed in ApoA1, HDL-C, total cholesterol, triglycerides, LDL-C, or VLDL, for either tumor stage or histological grade.
Conclusion: ApoB levels appear to decline with advancing tumor stage in gastric adenocarcinoma, suggesting a potential role as a marker to evaluate disease burden. While no association was found with tumor grade, further validation in larger prospective studies incorporating metabolic and inflammatory covariates is warranted.
Methods: Fifty patients diagnosed with gastric adenocarcinoma were enrolled. Serum levels of total cholesterol, triglycerides, HDL-C, LDL-C, ApoA1, and ApoB were measured. Patients were categorized into early (stages I–II) and advanced (stages III–IV) tumor stages, as well as into moderately differentiated versus poorly differentiated grades. The Shapiro-Wilk test was used to assess data normality. Parametric and non-parametric tests were applied accordingly. A p-value < 0.05 was considered statistically significant.
Results: ApoB was the only parameter showing a significant association with tumor stage. Patients with advanced-stage GC had significantly lower mean ApoB levels compared to those in early stages (52.4 ± 2.6 vs. 63.4 ± 5.2 mg/dl, p = 0.042). No statistically significant differences were observed in ApoA1, HDL-C, total cholesterol, triglycerides, LDL-C, or VLDL, for either tumor stage or histological grade.
Conclusion: ApoB levels appear to decline with advancing tumor stage in gastric adenocarcinoma, suggesting a potential role as a marker to evaluate disease burden. While no association was found with tumor grade, further validation in larger prospective studies incorporating metabolic and inflammatory covariates is warranted.
Keywords: Adenocarcinoma, Stomach, Apolipoprotein B, Lipid Metabolism, Neoplasm Staging, Neoplasm Grading
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Contact us
Tel & Fax: (+98) 17-32450093
E-mail:
goums.ac.ir
yahoo.com